CEO Chat with Lakewood-Amedex: Revolutionizing Infection Treatment with Bisphosphocin | $LABT

Recently initiated under Zacks SCR coverage, Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) CEO Dr. Kelvin Cooper joins Zacks SCR's David Bautz to discuss the company's Bisphosphocin® class of antimicrobials. Dr. Cooper covers the platform's novel membrane-disrupting mechanism, its activity against biofilm and drug-resistant organisms in company testing, the ongoing Phase 2a trial in infected diabetic foot ulcers, regulatory considerations for a new antimicrobial class, and near-term milestones investors should watch for. https://scr.zacks.com/home/default.aspx https://lakewoodamedex.com/ 📍 Subscribe to Zacks SCR for all the latest updates on small and micro cap stocks. 📩 Sign up for our free Weekly Digest email here: https://scr.zacks.com/subscribe/free-... 00:00 Introduction to Lakewood Amadex Biotherapeutics 00:57 The Bisphosphocin Class: A New Antimicrobial Approach 02:54 Targeting Diabetic Foot Ulcers: A Strategic Choice 04:39 Trial Design and Success Metrics 06:17 The Importance of Anti-Biofilm Activity 07:00 Regulatory Considerations for Novel Antimicrobials 08:34 Industry Interest and the Future of Antimicrobials 10:06 Confidence in Clinical Success: Insights from Experience 11:41 Looking Ahead: Key Milestones for Investors #LABT #LakewoodAmedex #NASDAQ #smallcapstocks #smallcaps #investing _______________________________________________________________________ DISCLOSURE: The Zacks SCR analyst conducting this Chat hereby certifies that the views expressed accurately reflect the personal views of the analyst about the subject securities and issuer. Zacks SCR certifies that no part of any analyst’s compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this Chat. Zacks SCR believes the information used for the creation of this Chat has been obtained from sources considered to be reliable, but we can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer, for providing research coverage for a period of no less than one year. CEO/Fireside Chats, as mentioned here, are part of the service Zacks SCR provides, and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE: https://scr.zacks.com/disclaimer/defa...